Cullinan Therapeutics Inc

CGEM is in a Stage 2 advancing structure, supported by a Bearish Exhaustion pattern suggesting sellers are losing control. However, the recent pullback through the rising 9 and 20 EMAs signals weakening short-term momentum. Price remains above the rising 50 SMA and 200 DMA, and RSI and Options Score are neutral, offering no immediate timing edge. Execution should be deferred until a shallow pullback is absorbed at the dynamic EMA support zone, confirming continued trend validity. A decisive close below the 50 SMA would invalidate the medium-term bullish bias.

• ↑Phase 3 trial for zipalertinib in NSCLC met primary PFS endpoint.
• ↑Six analysts rate CGEM a Buy with an average price target of $32.14.
• ↓Deep losses: adjusted Q2 EPS of –$0.81 vs –$0.80 estimate.